TABLE 1.
Clinical and demographic characteristics of the study participants.
| NR (n = 37) | RE (n = 53) | p value | |
|---|---|---|---|
| Age (year) | 5.25 (2.79–6.59) | 3.17 (1.75–5.54) | |
| Sex (Male/Female) | 28/9 | 27/26 | |
| C 0 (μg/mL) | 66.65 (56.60–86.98) | 62.20 (52.40–71.50) | 0.12 |
| Number of ASMs a | |||
| 1 | 0 | 53 | |
| 2 | 10 | 0 | |
| 3 | 22 | 0 | |
| 4 | 5 | 0 | |
| ALT (U/L) | 10.00 (8.00–13.75) | 12.00 (9.00–13.50) | 0.12 |
| AST (U/L) | 23.00 (21.00–27.75) | 28.00 (25.50–32.00) | <0.01 |
| Urea (mmol/L) | 4.74 (3.89–6.05) | 4.40 (3.87–5.00) | 0.19 |
| Scr (μmol/L) | 29.71 ± 9.06 | 26.65 ± 6.59 | 0.07 |
| Cys C (mg/L) | 0.89 (0.72–1.01) | 0.77 (0.71–0.89) | 0.16 |
Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferases; Cys C, cystatin C; Scr, serum creatinine.
a
Patients in RE group took VPA monotherapy, while cases in NR group were treated with various ASMs. ASMs include VPA, oxcarbazepine, topiramate, levetiracetam, clonazepam, lamotrigine, vigabatrin, lacosamide, perampanel.